Trial Profile
A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Baminercept (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Biogen
- 31 Mar 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 02 Sep 2010 New trial record